Patient Login
Search
Breast cancer screening isn’t just a medical issue. It’s a market failure. When detected at stage one, breast cancer is nearly 99% survivable, typically requiring less aggressive treatment and resulting in better outcomes. Early detection allows women to remain fully present - at work, with family and free from the devastation of a late-stage diagnosis.
Yet standard screening in the U.S. routinely excludes women under 40, the demographic experiencing rising breast cancer rates, and fails the nearly half of women with dense breast tissue, where mammograms can miss cancers. The result: an estimated 42,170 U.S. women will die from breast cancer in 2025. That figure reflects a system where early detection and tailored screening still fall short.
Now a generation of women founders and investors who lived those failures are rebuilding the system. Bailey Renger, founder of BeSound, is one of them. Her vision is simple and radical at once. As Renger shared in a Zoom interview, “The goal is to make breast cancer a disease women no longer die from.”
Innovating Breast Cancer Screening and Why It Matters
Renger’s conviction comes from personal experience. After facing a health scare involving a solid mass, she struggled to receive imaging tests that could provide clarity. Insurance restrictions delayed access, preventing her from receiving objective data about her own body. That gap became her mission for BeSound.
BeSound works with OB/GYN and other medical practices to bring ultrasound and photoacoustic imaging technology directly into their offices, supported by independent physician groups. Though not a replacement for mammograms, the platform provides supplemental screening options.